Kalbe Farma (KLBF.IJ) Sustainable Moat Underpins Steady Earnings Growth
1Q25 strong earnings were driven by cost-efficiency; we expect 2Q25 revenue to normalize post-Eid yet still on-track to meet FY25F guidance.
479 Views
Kalbe Farma - Healthy FY25 Growth Outlook Intact Despite ST Rupiah Headwinds
Solid prescription revenue and operating efficiency drove strong 9M24 net and core profit growth of 15.2%/10% yoy. We estimate healthy FY25 net...
395 Views
Kalbe Farma - Improving Growth Outlook from Higher Margins and Steady Revenue
We see catalysts from steady 2H24 revenue (+8.8% yoy), improved margins, & potential FDA approvals for high-margin specialty products.
341 Views
Kalbe Farma - Resilient Growth Outlook at Reasonable Valuation
Unbranded Generic and distribution to drive FY24F top line, while CH and Nutrition revenue normalized. We raised FY24-25F NP by 4.5-2.9%
275 Views
Kalbe Farma (KLBF.IJ) - Resilient Growth Outlook at Reasonable Valuation
Unbranded Generic and distribution to drive FY24F top line, while CH and Nutrition revenue normalized We raised FY24-25F NP by 4.5-2.9%, driven by...
347 Views